INTERLEUKIN-5 AND EOSINOPHIL CATIONIC PROTEIN IN NASAL LAVAGES OF RHINITIS PATIENTS

被引:27
作者
GARRELDS, IM
TVELD, TD
NAHORI, MA
VARGAFTIG, BB
VANWIJK, RG
ZIJLSTRA, FJ
机构
[1] UNIV ROTTERDAM HOSP,DEPT ALLERGOL,3000 DR ROTTERDAM,NETHERLANDS
[2] INST PASTEUR,UNITE PHARMACOL CELLULAIRE,F-75724 PARIS 15,FRANCE
关键词
INTERLEUKIN-5; EOSINOPHIL CATIONIC PROTEIN (ECP); HOUSE DUST MITE; FLUTICASONE PROPIONATE; AQUOUS NASAL SPRAY; RHINITIS;
D O I
10.1016/0014-2999(95)00049-Q
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The production of interleukin-5 and eosinophil cationic protein (ECP) in the nasal cavity was examined in 24 patients with rhinitis who were allergic to the house dust mite. During a double-blind placebo-controlled cross-over study, fluticasone propionate aqueous nasal spray (200 mu g) was administered twice daily for 2 weeks. After four basal nasal lavages provocation with house dust mite extract was performed and nasal lavages were collected every hour for 9.5 h. Interleukin-5 was present in detectable amounts in nasal lavages from patients allergic to house dust mite. Nasal challenge with house dust mite extract caused immediate nasal symptoms and increased levels of interleukin-5. Between 3.5 and 8.5 h after the challenge symptoms recurred and interleukin-5 levels increased, reflecting a late phase reaction. Eosinophil cationic protein, a marker of activated eosinophils, was released between 6.5 and 9.5 h after challenge. Treatment with fluticasone propionate (as an aqueous nasal spray) significantly decreased the evoked interleukin-5 and ECP levels in the late phase reaction. This response was correlated with an improved symptom score. This could indicate that the number and activity of eosinophils are increased during the late phase allergic reaction, a response that is inhibited by corticosteroids.
引用
收藏
页码:295 / 300
页数:6
相关论文
共 16 条
[1]  
BRADDING P, 1993, J IMMUNOL, V151, P3853
[2]  
CULPEPPER JA, 1985, J IMMUNOL, V135, P3191
[3]  
DEGRAAFINT VC, 1995, IN PRESS CLIN EXP AL
[4]   EFFECT OF AN INHALED CORTICOSTEROID ON AIRWAY INFLAMMATION AND SYMPTOMS IN ASTHMA [J].
DJUKANOVIC, R ;
WILSON, JW ;
BRITTEN, KM ;
WILSON, SJ ;
WALLS, AF ;
ROCHE, WR ;
HOWARTH, PH ;
HOLGATE, ST .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 145 (03) :669-674
[5]  
DURHAM SR, 1992, J IMMUNOL, V148, P2390
[6]   EFFECT OF FLUTICASONE PROPIONATE AQUEOUS NASAL SPRAY TREATMENT ON PLATELET-ACTIVATING-FACTOR AND EICOSANOID PRODUCTION BY NASAL-MUCOSA IN PATIENTS WITH A HOUSE-DUST MITE ALLERGY [J].
GARRELDS, IM ;
DEGRAAFINTVELD, T ;
JANSEN, APH ;
VANWIJK, RG ;
ZIJLSTRA, FJ .
MEDIATORS OF INFLAMMATION, 1994, 3 (05) :381-385
[7]   RELATIONSHIP BETWEEN THE EARLY, LATE, AND RECHALLENGE REACTION TO NASAL CHALLENGE WITH ANTIGEN - OBSERVATIONS ON THE ROLE OF INFLAMMATORY MEDIATORS AND CELLS [J].
ILIOPOULOS, O ;
PROUD, D ;
ADKINSON, NF ;
NORMAN, PS ;
KAGEYSOBOTKA, A ;
LICHTENSTEIN, LM ;
NACLERIO, RM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1990, 86 (06) :851-861
[8]   MAST-CELLS AND MEDIATORS IN THE NASAL-MUCOSA AFTER ALLERGEN CHALLENGE - EFFECTS OF 4 WEEKS TREATMENT WITH TOPICAL GLUCOCORTICOID [J].
JULIUSSON, S ;
HOLMBERG, K ;
KARLSSON, G ;
ENERBACK, L ;
PIPKORN, U .
CLINICAL AND EXPERIMENTAL ALLERGY, 1993, 23 (07) :591-599
[9]  
MOSMANN TR, 1986, J IMMUNOL, V136, P2348
[10]  
NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597